Study Objectives: Excessive sleepiness is a common symptom in Prader-Willi syndrome (PWS), and it negatively impacts the quality of life. Obstructive sleep apnea and narcolepsy phenotypes have been reported in PWS. We characterized sleep disorders in a large cohort of adults with PWS. Methods: All consecutive patients with genetically confirmed PWS unselected for sleep-related symptoms, underwent a clinical interview, polysomnography, and multiple sleep latency tests (MSLT, n = 60), followed by long-term (24 hours) polysomnography (n = 22/60). Results: Among 60 adults evaluated (57% female, aged 25 ± 10 years, body mass index: 39 ± 12 kg/m 2 ), 67% reported excessive sleepiness. According to the sleep study results, 43% had a previously unrecognized hypersomnia disorder, 15% had an isolated sleep breathing disorder, 12% had combined hypersomnia disorder and untreated breathing sleep disorder, and only 30% had normal sleep. Isolated hypersomnia disorder included narcolepsy in 35% (type 1, n = 1, and type 2, n = 8), hypersomnia in 12% (total sleep time >11 hours, n = 2, and MSLT <8 minutes, n = 1), and borderline phenotype in 53% (≥2 sleep onset in REM periods and MSLT >8 minutes, n = 10, and 8 minutes < MSLT < 10 minutes, n = 4). Sleep breathing disorders, isolated and combined, included obstructive sleep apnea (n = 14, already treated in seven), sleep hypoxemia (n = 1) and previously undiagnosed hypoventilation (n = 5). Modafinil was taken by 16 patients (well tolerated in 10), resulting in improved sleepiness over a mean 5-year follow-up period. Conclusion: Sleepiness affects more than half of adult patients with PWS, with a variety of hypersomnia disorder (narcolepsy, hypersomnia, and borderline phenotypes) and breathing sleep disorders. Earlier diagnosis and management of sleep disorders may improve sleepiness, cognition, and behavior in these patients.
INTRODUCTION
Prader-Willi syndrome (PWS) is a complex multisystem genetic disorder in which obesity is a dominant feature. The condition is caused by the lack of expression of paternalorigin imprinted alleles on chromosome 15q11-q13 due to paternal deletion of this region (65%-75% of individuals), maternal uniparental disomy 15 (20%-30%), or an imprinting defect (1%-3%). 1 PWS is the most common genetic syndrome that causes marked human obesity. The birth incidence of PWS is estimated to be approximately 1 in 20,000, and the population prevalence is estimated to be 1 in 50,000.
1 PWS is characterized by severe neonatal hypotonia and suckling deficiency, with feeding problems in infancy and excessive weight gain starting in early childhood, leading to obesity due to hyperphagia and lack of satiety. Other characteristic features include scoliosis, dysmorphic features, learning difficulties, cognitive impairment, and behavioral problems continuing into adulthood. Most patients have hypogonadism and growth hormone deficiency, leading to a short stature. 1, 2 Obesity remains a major issue in adults with PWS and can lead to type 2 diabetes mellitus, hypertension, dyslipidemia, obstructive sleep apnea (OSA), limb edema, and cardiac or respiratory failure. 1 A frequent symptom in PWS patients is excessive sleepiness, which often begins in early childhood and negatively impacts the everyday life of patients. [3] [4] [5] [6] Indeed, excessive sleepiness with increased occurrence of napping and reduced daytime activity has been shown to disrupt the daily routines and quality of life of children with PWS and their families. 4, 5 It can interfere with the patient's learning abilities, affect their psychological status, and worsen behavior disorders. 7 Sleepiness in these patients was initially attributed to OSA, 6, 8 which in turn is related to obesity. 9 However, sleepiness often persists in patients with PWS after the treatment of OSA using nocturnal continuous positive airway pressure (CPAP) 6, 8 and after weight loss. 10 Narcolepsy phenotypes, including frequent sleep onset in REM periods (SOREMPs), sometimes associated with cataplexy, 6, 11, 12 have been documented in nocturnal sleep studies followed by multiple sleep latency tests (MSLT) in small series of 1 to 21 patients, 3, 8, [12] [13] [14] [15] suggesting that in these patients, sleepiness may be a symptom of a narcolepsy phenotype. When all patients from eight studies were pooled, objective sleepiness (MSLT<5 minutes) was observed in 29/72 (40%) cases. 16 It has been hypothesized that sleepiness in PWS may be centrally mediated, reflecting a primary hypothalamic dysfunction that characterizes PWS per se. [13] [14] [15] Some case studies have reported long
Statement of Significance
Prader-Willi syndrome (PWS) is a genetic disorder characterized by obesity due to hyperphagia caused by hypothalamic defects, cognitive impairment, and behavioral disturbances. Here, we systemically studied 60 consecutive adult patients with PWS and found that 2/3 of them complained of sleepiness. More than half of the patients had some form of hypersomnia disorder, mostly a borderline phenotype, sometimes associated with comorbid breathing sleep disorder. Considering the high prevalence of sleepiness in PWS, we recommend that all patients with PWS undergo sleep assessments including polysomnography and multiple sleep latency tests.
sleep times (exceeding 10 hours) in PWS patients. 4 However, to date, sleep excess in PWS patients has not been precisely documented, for example, through long-term (24-hour) sleep recordings. In addition, identification of the cause of excessive sleepiness would enable the introduction of a specific treatment with potential important clinical and social benefits.
In this study, based on a systematic and complete assessment of nighttime and daytime sleep patterns in a large cohort of adults with PWS unselected for sleep disturbances, the objective was to characterize sleep and sleepiness and to implement the appropriate treatment.
METHODS

Subjects
Between October 2008 and September 2015, we prospectively considered for participation in this study all adults (age range 16-54 years) with genetically confirmed PWS regularly followed in the French National Reference Centre for adults with PWS at the Nutrition Department of Pitié-Salpêtrière university hospital in Paris, regardless of the symptoms of sleep disorders ( Figure 1 ). Patients with major behavioral or psychiatric problems were excluded. The Rare Diseases Program is a national clinical and research program led by the French Health Ministry since 2006 to encourage all patients with a suspected rare disease to be systematically referred for diagnosis, research investigation, treatment, and DNA collection to national reference centers. For PWS, the national center includes four sites: Pitié-Salpêtrière Hospital in Paris, Hendaye Hospital, Purpan Hospital in Toulouse, and Necker Hospital in Paris. All patients and families signed an informed consent form enabling the results of their routine clinical interview, questionnaire, and tests (including DNA) to be collected in a database and used for research purposes.
Nutritional and Biological Measures
The demographic characteristics, genetics, medical history, PWS course, and treatment were systematically collected at the National Reference Centre for adult patients with PWS in our hospital. 17 Biochemical parameters were measured using routine techniques, the Homeostasis Model Assessment, an index of insulin resistance, was calculated, and dyslipidemia was defined as previously described.
17
Sleep Evaluation
Clinical and instrumental sleep examinations were performed in the Sleep Disorders Unit and National Reference Center for Narcolepsy, Hypersomnia, and Kleine-Levin Syndrome at the same university hospital and included a systematic faceto-face sleep interview (of the patients and their caregivers) about sleepiness, cataplexy, sleep paralysis, hypnagogic hallucinations, sleep attacks (defined in accordance with the International Classification of Sleep Disorders-3 as falling asleep with little or no prodromal symptoms), habitual snoring, witnessed apneas, urinating more than once/night, and morning headache. Excessive sleepiness was defined as reported by the patients and/or their caregivers, independent of a score on the Epworth sleepiness scale greater than 10. 18 Because the sleep tests were considered a routine systematic evaluation in patients at high risk of sleep apnea and secondary narcolepsy, drugs were not changed (and were difficult to withdraw) for the sleep tests, including antipsychotics and antidepressant drugs. The DQB1*0602 genotype of class II human leukocyte antigen genotype was determined. Analysis of diurnal arterial blood gases was performed to detect hypoventilation in association with severe obesity. All patients underwent an attended full-night video polysomnography with eight electroencephalographic channels, followed the next day by MSLT consisting of five nap opportunities at 08:00 am, 10:00 am, 12:00 pm, 02:00 pm, and 04:00 pm. The nap sessions were terminated after 20 minutes if no sleep occurred and after 15 minutes of sleep if sleep occurred. 19 For patients who reported more than 9 hours of sleep a day, the sleep study was extended for the next 24 hours to a long-term, in-hospital sleep recording, with a second, uninterrupted night followed by an attempt to sleep for as long as possible the next morning and afternoon while lying in the dark. 20 For patients treated with CPAP for previously diagnosed sleep apnea, CPAP was applied during all sleep tests. All kinds of food (except their scheduled, personal diet) were removed from the view of the patients in the sleep disorder unit to avoid conflicts about food. Sleep stages, 21 arousals, 22, 23 periodic leg movements, and respiratory events were scored by visual inspection according to the standard criteria. 24 Concerning the different types of hypersomnia, we defined, in consideration of the 2012 international sleep disorders criteria 25 (1) narcolepsy with and without cataplexy as a mean sleep latency ≤8 minutes in MSLT and at least two SOREMPs, recently termed type 1 and type 2; (2) hypersomnia with long sleep time as a total sleep time ≥11 hours on the 24-hour sleep recording; (3) hypersomnia with normal sleep time as a mean sleep latency ≤8 minutes in MSLT, less than two SOREMPs, and a total sleep time <11 hours on the 24-hour sleep recording. In addition, as many patients had borderline results, we defined (1) SOREMPs disorder as at least two SOREMPs during MSLT, regardless of MSLT latency, and (2) borderline hypersomnia as the mean sleep latency >8 minutes and <10 minutes in MSLT with a total sleep time <11 hours on the 24-hour sleep recording.
Concerning breathing sleep disorders, we defined, based on the international criteria 25 (1) untreated sleep apnea as an apnea-hypopnea index >15/hour; (2) treated sleep apnea as an apnea-hypopnea index <5/hour on a sleep study performed on CPAP and a CPAP adherence >4 hours/day; (3) sleep hypoxemia as >5 minutes of sleep with SpO 2 <88%; and (4) hypoventilation as a diurnal PaCO 2 > 45 mmHg.
In patients with excessive sleepiness with no or treated sleep breathing disorders and without a high risk of behavior disorder exacerbation (established with the patient's psychiatrist), modafinil was prescribed with a starting dose of 100 mg per day. The dose was subsequently increased if there was no clinical improvement or side effect. The efficacy of modafinil was evaluated by comparing the Epworth sleepiness score before and after treatment and as reported by the patients and/or their caregivers. A sleep study was not performed after the stimulant treatment.
Statistical Analysis
The description of the characteristics of the study participants was based on calculations of means with corresponding standard deviations for normally distributed continuous variables and relative frequencies for categorical variables. To compare patients with normal sleep to those with narcolepsy or hypersomnia, we used chi-square tests or Mann-Whitney tests, depending on the categorization of the variable and distribution of the data. A value of p < .05 was considered statistically significant. Analyses were performed with IBM SPSS (version 21).
RESULTS
Clinical Characteristics of the PWS
As shown in the flowchart (Figure 1 ), 81 PWS patients were considered for participation in this study, 11 were excluded for major behavioral or psychiatric problems, and 60 completed the study. Among the patients, only nine (15%) had had a previous sleep evaluation in another setting with the only purpose of detecting sleep apnea. Clinically significant OSA had been diagnosed and treated in seven of the patients. After the initial selection at the PWS center of patients who could potentially accept the constraints of the sleep tests, only one of the referred patients refused to stay in the sleep unit, lying on the floor, and shouting despite the presence of his parents. One patient broke the recording device during an episode of anger. Many patients wandered in the sleep unit between sleep tests and frequently tried to enter the kitchen or the rooms of other patients to grab food, but they were kindly dismissed and redirected by the team, who adopted the habit of removing any food from their view. The genetic, demographic, clinical, and biological characteristics of study patients are presented in Table 1 (first column). Diurnal arterial blood gases were obtained in 67% of patients and showed diurnal hypoventilation in five patients, two of them with untreated OSA and all of them with a body mass index greater than 35 kg/m 2 .
Sleep and Sleepiness Characteristics
The human leukocyte antigen (HLA) genotype and sleep-related clinical characteristics are reported in Table 2 (first column). The HLA genotype DQB1*0602 was found in only three (5%) patients, one of whom had narcolepsy type 2 and two who had no sleep disorders. Complaints of excessive sleepiness were reported by 40 (67%) patients, among whom the Epworth score was greater than 10 in 29 (73%) patients, lower than or equal to 10 in 22% (n = 9 patients), and unavailable in 5% (n = 1). Only one patient had an Epworth score greater than 10 without any complaint of excessive sleepiness. Five patients reported partial or complete cataplexy, all five showing a narcolepsy phenotype on MSLT. The three patients with reported sleep time >11 hours had hypersomnia with, respectively, 11 hours 39 minutes, 12 hours 24 minutes, and 12 hours 30 minutes of sleep over 24 hours. Sleep attacks were reported by eight patients, among whom six had narcolepsy and two had hypersomnia. Sleep paralysis was reported by two patients (narcolepsy, n = 1, SOREMPs disorder in MSLT, n = 1). None had hypnagogic hallucinations. Habitual snoring, witnessed apneas, and urinating more than once/night were common symptoms but were not specifically associated with the presence of sleep breathing disorders. Instrumental sleep characteristics are reported in Table 3 (first  column) . According to the sleep recordings (Figure 2 ), 43% of patients had a previously unrecognized hypersomnia disorder; 15% of patients had an isolated sleep breathing disorder, which was already treated in 44% of cases; 12% of patients had combined hypersomnia disorder and untreated breathing sleep disorder; and only 30% had normal sleep. Among the 26 patients with isolated hypersomnia disorder, 35% had narcolepsy (type 1, n = 1, and type 2, n = 8,), 12% had hypersomnia (total sleep time > 11 hours, n = 2, and MSLT<8 minutes, n = 1), and 53% a borderline phenotype (≥2 SOREMPs and MSLT >8 minutes, n = 10, and 8 minutes < MSLT < 10 minutes, n = 4). Twenty patients had one or two sleep breathing disorders, associated or not associated with hypersomnia disorder; these included OSA (n = 14, already treated in seven), sleep hypoxemia (n = 1), and previously undiagnosed hypoventilation (n = 5). Tables 1-3 show the genetic, demographic, clinical, biological, and instrumental characteristics of PWS patients with normal sleep and those with narcolepsy/hypersomnia (second and third columns, respectively). Body weight was significantly higher in patients with narcolepsy/hypersomnia, and body mass index was not significantly different but was clinically higher in this group. Therefore, the comparison between the two groups was adjusted for the body mass index. Fasting insulinemia was higher in patients with narcolepsy/hypersomnia than in those with normal sleep. However, after correction for the body mass index, there was no genetic, clinical, biological, or therapeutic difference between the two groups ( Table 1) . Though the Epworth score did not differ between the two groups, excessive daytime sleepiness was reported three times more often (11 of 12 patients) in the narcolepsy/hypersomnia group, and sleep attacks manifested as a very specific symptom for narcolepsy/ hypersomnia with no other differences in sleep-related symptoms ( Table 2) . As expected, MSLT and total sleep time were different between the two groups, with no other differences in instrumental sleep characteristics (Table 3) .
Comparison Between Patients With Normal Sleep and Patients With Narcolepsy/Hypersomnia
Treatment of Sleep Disorders
In patients with untreated sleep breathing disorders, CPAP was prescribed for patients with OSA and noninvasive ventilation was prescribed for those with hypoventilation. As shown in Figure 3 , modafinil was offered to 21/40 patients with excessive sleepiness (11 with narcolepsy/hypersomnia, 7 with borderline phenotype, and 2 with normal sleep). Five patients declined the prescription because they (and/or their caregivers) were worried about side effects, particularly increased irritability or aggressive behavior. Modafinil was taken at a dose of 100 mg/day by eight patients and 200 mg/day by the other eight patients. Two patients immediately developed repeated panic attacks (n = 1) and depressive mood (n = 1) under modafinil, which stopped after the drug was withdrawn. The remaining 14 patients had durably improved levels of sleepiness, according to the caregivers and patients. The Epworth score decreased from 14 ± 5 to 9 ± 4 (p = .004), with a duration of treatment of 3.6 ± 3.1 years. The body mass index of the patients did not change significantly with treatment. In four patients, however, modafinil was stopped because of anxiety, aggressiveness, and delirious episodes, with side effects appearing over a 0.1-to 1.5-year period and regressing quickly after medication cessation. Eventually, 10 patients continued modafinil in the long term (4.9 ± 2.8 years). We recently suggested pitolisant (a new drug that increases brain histamine with a low frequency of irritability) to two patients who stopped modafinil because of side effects, with one case of good effectiveness without side effects and one case lost to follow-up.
DISCUSSION
In this study, a complete sleep evaluation (including MSLT and long-term sleep monitoring) was systematically performed in a large cohort of adults with PWS. Despite the high prevalence of self-reported sleepiness (67% of patients), only 15% of the patients had been previously explored, diagnosed, and treated for OSA, half of them remaining sleepy despite adequate CPAP. Almost half of the patients had a previously unrecognized isolated hypersomnia disorder, including narcolepsy (35%), hypersomnia (12%), and borderline narcolepsy/hypersomnia phenotype (53%). In parallel, 30% of patients had a sleep breathing disorder, associated or not associated with hypersomnia disorder, mainly consisting of OSA (previously diagnosed and treated in half of the cases), whereas 8% of patients presented previously undiagnosed hypoventilation. Our cohort was characterized by a classical repartition between deletions and uniparental disomy, and the prevalence of obesity, endocrine, and metabolic features was in line with the literature about the syndrome. 1 Although excessive sleepiness is known to be a common symptom in PWS, already present in early childhood, which Total sleep time > 11 hours 3 (5) 0 (0) 25 (2) .224
Sleep stages 1-2 (% total) 60 ± 19 56 ± 10 61 ± 32 1.000
Sleep stages 3-4 (% total) 22 ± 10 22 ± 10 25 ± 13 .833
REM sleep (% total) 22 ± 8 21 ± 6 27 ± 9 .127
Data are expressed as mean ± SD or n (%). p is referred to comparison between patients with normal sleep and patients with hypersomnia or narcolepsy; p value < .05 are given in bold. AHI = apnea-hypopnea index; SOREMP = sleep onset in REM period. can negatively impact the quality of life, learning, and psychological status, as well as destabilize behavior disorders, 4, 5, 7 clinical and instrumental sleep examinations are not routinely performed for PWS patients, as shown again here. We found that 73% of patients with excessive sleepiness reported by patients and/or caregivers had an abnormal score on the Epworth sleepiness scale, and only one patient scored higher than 10 on the scale without spontaneous complaints of excessive sleepiness. The data suggest that the Epworth sleepiness scale may be an appropriate screening tool for excessive sleepiness in adults with PWS (despite cognitive impairments), and face-to-face interviews with patients and/or their caregivers about excessive sleepiness appear more sensitive. Data on other symptoms, more specific to hypersomnia, were also successfully collected through face-to-face interviews with patients and caregivers, including cataplexy (n = 5, all of them having MSLT typical of narcolepsy), a reported sleep time > 11 hours a day (n = 3, all of them having hypersomnia with long sleep time on sleep recordings), sleep attacks (6/10 patients with narcolepsy and 2/6 patients with hypersomnia), and sleep paralysis (two patients). Cataplexy has been reported in some children and adults with PWS 6, 11, 12 without any association with the HLA DQB1*0602 genotype. 12, 13 This result was confirmed in our study. Sleep paralysis and hypnagogic hallucinations have rarely been reported in other studies and were rare (sleep paralysis) or absent (hypnagogic hallucinations) in the current study as well, 6 suggesting they are infrequent in the PWS hypersomnia phenotype. These results underline the importance of interviewing patients and/or their caregivers not only about excessive sleepiness but also about other symptoms related to narcolepsy/hypersomnia. On the other hand, symptoms usually related to sleep breathing disorders (heavy snoring, witnessed apneas, urinating more than once/night, morning headaches) were not specifically associated with the presence of objective sleep-related breathing disorders in our study, suggesting these symptoms are poorly sensitive in PWS. However, the cognitive impairment in most of our patients limited face-to-face interviews and probably led to the underestimation of symptoms.
Because of obesity and the short stature of patients, excessive sleepiness in this population is commonly attributed to OSA. 8, 9 We actually found a moderate (22%) prevalence of moderate-to-severe OSA, which was already treated only in half of the cases. Obesity is also considered a major cause of hypoventilation, which can be present in PWS 13 and has important management implications, especially because cardiorespiratory failure has often been reported as the cause of death for PWS patients older than 15 years. 26 We found diurnal hypoventilation in 5 out of 39 patients who underwent arterial blood gas analyses, two of them with untreated OSA, and all of them with a body mass index greater than 35 kg/m 2 . This result suggests it may be of importance for clinical management to systematically perform arterial blood gas analyses for PWS patients with such a high body mass index.
Despite the moderate prevalence of OSA in PWS patients, it was previously reported 8, 10 and confirmed in this study that excessive sleepiness can persist in some patients with PWS after sleep apnea treatment and can be present in PWS patients without sleep-related breathing disorders. 3, 6, 13, 15 Consistent with previous reports, 3,8,12-15 we found a high prevalence of different degrees of REM dysregulation, from narcolepsy with cataplexy to multiple SOREMPs without a short sleep latency in the MSLT. For the first time in this study, a 24-hour sleep recording was performed after the first night polysomnography and MSLT for PWS patients reporting more than 9 hours of sleep a day with the aim to document the previously reported but not instrumentally documented excessive sleep time in PWS patients. 4 This long-term sleep monitoring procedure, previously standardized in our sleep disorders unit to diagnose idiopathic hypersomnia with long sleep time, 20 identified three patients with hypersomnia with long (≥11 hours) sleep time among 22 patients reporting more than 9 hours of sleep a day. These three patients had excessive sleepiness that was not explained by the one-night polysomnography and MSLT results, underlining the importance of asking about the total sleep time and completing a 24-hour sleep recording for patients who report more than 9 hours of sleep a day. This high prevalence of previously unrecognized hypersomnia disorder and breathing sleep disorders in a large cohort of adults with PWS strongly suggests that PWS patients should be regularly and systematically interviewed about sleep and sleepiness complaints, and their complaints should be investigated with adequate sleep tests (i.e., not restricted to sleep apnea screening). Here, 12 adults with PWS did not undergo a sleep study because of major behavioral and/or psychiatric problems and nine declined the study. On the other hand, these tests were feasible in the majority of a cognitively and behaviorally impaired population, provided that the caregivers were convinced of their usefulness and that food was hidden from view. However, it would probably be easier to explore sleep in younger PWS patients because behavioral problems appear and/or are aggravated in adulthood. 1 Moreover, it has been shown that in PWS patients, excessive sleepiness can interfere with learning, affect psychological status, and destabilize behavior disorders, 7 highlighting the importance of investigating and treating sleep and sleepiness as early as possible. Here, we observed that small (100-200 mg/day) doses of modafinil were well tolerated and beneficial in 10/16 patients. The side effects (irritability, anxiety, panic attacks, depressive mood, aggressive behavior) found in 6/16 patients were somewhat expected, as they are (although less frequent) side effects in patients with primary narcolepsy and idiopathic hypersomnia. 27 Here, they did not always appear during the first weeks of treatment and rapidly disappeared after cessation of the drug, which suggests that it is worth trying the drug and evaluating its benefits/risks on an individual basis. Treatment with modafinil is not associated with the development of either dependence or tolerance. 28 Use of modafinil is currently established for narcolepsy and idiopathic hypersomnia in adults. A similar, open-label pilot study showed good efficacy for modafinil (reduced scores on the Epworth sleepiness scale) without side effects in nine children and adolescents with PWS plus a complaint of excessive sleepiness and no sleep disordered breathing. 29 The risk of increasing irritability and aggressiveness in one third of PWS patients when using modafinil suggests that it would be interesting to try pitolisant, the new anti-H3 stimulant, in patients with PWS. The benefits of pitolisant on sleepiness are similar to those of modafinil, 30 but the former seems to induce less irritability, both in trials and in our clinical experience with more than 200 patients. 31 Apart from the clinical aspects of sleepiness in PWS, one may wonder whether the presence of narcolepsy/hypersomnia in PWS correlates with the genetic, metabolic, and hormonal features in patients. Surprisingly, we found no differences except for a higher weight (but not a statistically higher body mass index) in the narcoleptic/hypersomnia group compared to the normal sleep group. In our study, as well as in previous series, 15, 32 the deletion/uniparental disomy ratio did not differ between patients with narcolepsy/hypersomnia and patients with normal sleep. Similarly, there was no association with the HLA DQB1*0602 genotype (associated with narcolepsy type 1), as found in smaller series. 12, 15 In accordance with our results, previous studies showed that obese PWS patients had more frequent excessive sleepiness than nonobese PWS patients, 10, 14, 33 raising the possibility of a common hypothalamic origin of excessive sleepiness and obesity in PWS. Features of PWS including appetite dysregulation leading to obesity, hypogonadism, lack of growth hormone, decreased level of sex hormones, labor abnormalities, temperature instability, and abnormalities in ventilator control, point to the hypothalamus as the probable site of dysfunction in the PWS brain. 34 In conclusion, clinical and instrumental sleep examinations should be performed routinely in PWS patients, possibly in childhood, to identify and treat sleep disorders that contribute to excessive sleepiness. Modafinil is well tolerated by 2/3 of patients and is beneficial for excessive sleepiness. The consequent early control of excessive sleepiness could improve cognitive and psychological development and prevent behavior disorders with potential major clinical and social implications for PWS patients and their families.
